Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Alexander Bukreyev

Alexander Bukreyev

University of Texas, USA

Title: Ebolavirus GP stalk-specific antibodies from survivors effectively target multiple steps of viral infection

Biography

Biography: Alexander Bukreyev

Abstract

Recent studies suggest that some glycoprotein (GP) specific monoclonal antibodies (mAbs) can protect experimental animals against the filovirus Ebola virus (EBOV). Multiple mAbs have been isolated previously from blood samples of human survivors of natural Bundibugyo ebolavirus (BDBV) infection (Flyak A. et al., Cell 2016). A panel of mAbs from four individual donors has been selected to study the mechanisms of infection inhibition. BDBV41 and BDBV289 mAbs specific to GP glycan cap (GC) inhibited virus attachment to the cells, whereas stalk-specific BDBV259, BDBV317 and BDBV223 mAbs were able to traffic to endosomal compartments together with virions and block the late steps of entry. BDBV270 and BDBV289 GC mAbs and BDBV317 mAb targeting membrane proximal external region (MPER) dose-dependently inhibited cell-to-cell viral transmission, which corresponded to the observed differences in mAb efficiency against high multiplicity of infection. The egress of virus from infected cells was suppressed by all glycan cap-specific mAbs, with strongest inhibition observed for the single non-neutralizing BDBV52 mAb. BDBV223 MPER mAb showed superior antiviral activity in vitro at each step of viral replication analyzed. In time course experiments, only MPER mAbs inhibited virus replication when added post-infection. The activation and degranulation of natural killer cells and monocyte phagocytosis relied mostly on IgG subclass, with the highest levels demonstrated by IgG3 mAbs. Finally, MPER mAbs conferred full protection against EBOV infection in mice. Altogether, these results suggest usage of mAbs with different epitope specificity could complement inhibition of multiple steps of filovirus infection through Fab- and Fc-mediated mechanisms.